Stabilitech Biopharma earns prestigious position on WHO list of vaccine developers
Burgess Hill, UK, 11 May 2020 STABILITECH BIOPHARMA LTD (“Stabilitech”), a UK biotechnology company developing next generation vaccines and biopharmaceuticals, announces today that, they have been recognised on a global level by the World Health Organisation (WHO) as a vaccine developer.
In addition to this global recognition, two Stabilitech board members, Dr Jeff Drew and Dr Elliot Bland were invited to participate in the Expert Group meetings on “Assays Development for Vaccines” and “Animal Models”.
This news is welcomed as, last week the company announced that it is currently in the process of securing further investment for its unique oral vaccine (OraPro-COVID-19 vaccine) that offers double immunity targeting both systemic and mucosal cells. In capsule form, the vaccine is self-administered and requires no cold chain storage.
Speaking on the appointment, Dr Drew highlighted: “The WHO is a pivotal player when it comes to vaccines, it sets all of the guidelines adopted by bio-pharmaceutical companies for vaccines development. Being added to the WHO’s list as a recognised vaccine developer is huge news for us and the UK biopharma sector, providing a level of global recognition that Stabilitech is an active player in finding a vaccine for COVID-19.”
“This is an important role contributing to the development of vaccines globally. Stabilitech’s expertise can be combined with those at other leading organisations such as Imperial College and Oxford,” added Dr Bland.
Dr Bland concludes: “The COVID-19 pandemic is a global challenge that requires international collaboration to find a solution. Joining the taskforce committee, means Stabilitech has direct input into COVID-19 vaccine development, making us part of the global community fight against Coronavirus.”
END OF PRESS RELEASE (WORDS 360)